Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Jeffrey

Showing results (631-640 of 651) with videos related to

Pageof 66
Sort By:
ACS Medicinal Chemistry Letters|July 10, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting SchizophreniaSusana Conde-Ceide, Carlos M Martínez-Viturro, Jesús Alcázar, et al.
ACS Chemical Neuroscience|August 20, 2014
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodentsMichael Bubser, Thomas M Bridges, Ditte Dencker, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2015
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophreniaSusana Conde-Ceide, Jesús Alcázar, Sergio A Alonso de Diego, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2018
The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu<sub>4</sub> PAM development candidateJoseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Annals of the New York Academy of Sciences|October 29, 2011
Advancing drug discovery for schizophreniaStephen R Marder, Bryan Roth, Patrick F Sullivan, et al.
ACS Chemical Neuroscience|February 28, 2012
The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's DiseaseZixiu Xiang, Analisa D Thompson, John T Brogan, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2016
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine coreMichael R Wood, Meredith J Noetzel, Julie L Engers, et al.
Journal of Medicinal Chemistry|August 17, 2013
Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptorJosé Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Francisca Delgado, et al.
Journal of Medicinal Chemistry|June 11, 2014
Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅)Mark Turlington, Chrysa Malosh, Jon Jacobs, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of Thieno[3,2-<i>b</i>]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Katherine E Crocker, Scott H Henderson, Rory A Capstick, et al.
Pageof 66

Showing results (631-640 of 651) with videos related to

Sort By:
Pageof 66
ACS Medicinal Chemistry Letters|July 10, 2015
Discovery of VU0409551/JNJ-46778212: An mGlu5 Positive Allosteric Modulator Clinical Candidate Targeting SchizophreniaSusana Conde-Ceide, Carlos M Martínez-Viturro, Jesús Alcázar, et al.
ACS Chemical Neuroscience|August 20, 2014
Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodentsMichael Bubser, Thomas M Bridges, Ditte Dencker, et al.
Bioorganic & Medicinal Chemistry Letters|December 20, 2015
Preliminary investigation of 6,7-dihydropyrazolo[1,5-a]pyrazin-4-one derivatives as a novel series of mGlu5 receptor positive allosteric modulators with efficacy in preclinical models of schizophreniaSusana Conde-Ceide, Jesús Alcázar, Sergio A Alonso de Diego, et al.
Bioorganic & Medicinal Chemistry Letters|December 4, 2018
The discovery of VU0652957 (VU2957, Valiglurax): SAR and DMPK challenges en route to an mGlu<sub>4</sub> PAM development candidateJoseph D Panarese, Darren W Engers, Yong-Jin Wu, et al.
Annals of the New York Academy of Sciences|October 29, 2011
Advancing drug discovery for schizophreniaStephen R Marder, Bryan Roth, Patrick F Sullivan, et al.
ACS Chemical Neuroscience|February 28, 2012
The Discovery and Characterization of ML218: A Novel, Centrally Active T-Type Calcium Channel Inhibitor with Robust Effects in STN Neurons and in a Rodent Model of Parkinson's DiseaseZixiu Xiang, Analisa D Thompson, John T Brogan, et al.
Bioorganic & Medicinal Chemistry Letters|May 18, 2016
Discovery and optimization of a novel series of highly CNS penetrant M4 PAMs based on a 5,6-dimethyl-4-(piperidin-1-yl)thieno[2,3-d]pyrimidine coreMichael R Wood, Meredith J Noetzel, Julie L Engers, et al.
Journal of Medicinal Chemistry|August 17, 2013
Dihydrothiazolopyridone derivatives as a novel family of positive allosteric modulators of the metabotropic glutamate 5 (mGlu5) receptorJosé Manuel Bartolomé-Nebreda, Susana Conde-Ceide, Francisca Delgado, et al.
Journal of Medicinal Chemistry|June 11, 2014
Tetrahydronaphthyridine and dihydronaphthyridinone ethers as positive allosteric modulators of the metabotropic glutamate receptor 5 (mGlu₅)Mark Turlington, Chrysa Malosh, Jon Jacobs, et al.
ACS Medicinal Chemistry Letters|May 14, 2025
Discovery of Thieno[3,2-<i>b</i>]pyridine-5-carboxamide and 2,3-Difluorobenzamide Negative Allosteric Modulators of Metabotropic Glutamate Receptor Subtype 5Katherine E Crocker, Scott H Henderson, Rory A Capstick, et al.
Pageof 66